News

Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Applications (sNDAs) for BRAFTOVI® (encorafenib) + MEKTOVI® …
Read More...

Sandoz, a global leader in off-patent (generic and biosimilar) medicines, announced that the European Commission (EC) granted marketing authorization in the European Union (EU) for a…
Read More...

BioNTech SE and Duality Biologics (Suzhou) Co. Ltd., a clinical-stage biotech company focusing on the discovery and development of next generation antibody-drug conjugate (“ADC”)…
Read More...

Merck, known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with…
Read More...

Novartis announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of Entresto…
Read More...

AstraZeneca has completed an exclusive global license agreement with KYM Biosciences Inc. for CMG901, a potential first-in-class antibody drug conjugate (ADC) targeting Claudin 18.2, a…
Read More...

GSK plc and SCYNEXIS, Inc. announced they have entered into an exclusive licence agreement for Brexafemme (ibrexafungerp tablets), a US FDA approved, first-in-class antifungal for the…
Read More...

Galapagos NV and NovAliX announced a strategic collaboration in which Galapagos’ research and discovery capabilities and exclusively related employees based in Romainville, France, will…
Read More...

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and the Government of the Republic of Kenya have finalized an agreement to establish an…
Read More...

In the lead up to World Theranostics Day this Friday, 31st March, GenesisCare, a leading global provider of integrated cancer care and research, and PreMIT, a Melbourne-based molecular…
Read More...

Merck, known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has granted full approval to KEYTRUDA, Merck’s anti-PD-1 therapy,…
Read More...

The Lupus Research Alliance (LRA) announced the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), a first-of-its-kind public-private partnership bringing people with lupus…
Read More...

Evotec SE announced that the Company has extended and expanded its strategic neurodegeneration partnership with Bristol Myers Squibb, originally signed in 2016. The initial partnership…
Read More...

Thermo Fisher Scientific and Arsenal Biosciences, Inc. (ArsenalBio) announced an update to our strategic collaboration to further the development of manufacturing processes for new…
Read More...

Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, announced its entry into a royalty agreement with RTW Investments, LP and…
Read More...

Théa Open Innovation (“TOI”), a sister company of ophthalmic specialty pharmaceutical company Laboratoires Théa, and Galimedix Therapeutics, Inc. (“Galimedix”), a clinical-stage…
Read More...

Regeneron Pharmaceuticals, Inc. announced that the European Commission (EC) approved Libtayo (cemiplimab) in combination with platinum-based chemotherapy for the first-line treatment of…
Read More...

Aquestive Therapeutics, Inc. announced it has expanded its exclusive license and supply agreement with Atnahs Pharma UK Limited (“Pharmanovia”), a global pharmaceutical company that…
Read More...

Regeneron Pharmaceuticals, Inc. and Sonoma Biotherapeutics, Inc. announced a collaboration to apply their scientific and clinical expertise and respective technology platforms to the…
Read More...

OncoVent Co., Ltd., a majority-controlled subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "Company"), yesterday entered into a license agreement with Orient…
Read More...